BTIG analyst Julian Harrison downgraded Prometheus (RXDX) to Neutral from Buy without a price target after the company agreed to be acquired by Merck (MRK) for $200 per share. The deal makes sense as it fills a "large void" in Merck’s pipeline, the analyst tells investors in a research note. Prometheus’ PRA023 remains in the pole positions for ulcerative colitis and Crohn’s disease, says the firm.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MRK: